LU81841A1 - Nouveaux composes azotes heterocycliques - Google Patents

Nouveaux composes azotes heterocycliques Download PDF

Info

Publication number
LU81841A1
LU81841A1 LU81841A LU81841A LU81841A1 LU 81841 A1 LU81841 A1 LU 81841A1 LU 81841 A LU81841 A LU 81841A LU 81841 A LU81841 A LU 81841A LU 81841 A1 LU81841 A1 LU 81841A1
Authority
LU
Luxembourg
Prior art keywords
radical
formula
compound
oxo
acid
Prior art date
Application number
LU81841A
Other languages
English (en)
French (fr)
Inventor
H Cairns
D Cox
N Chadwick
J Suschitzky
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of LU81841A1 publication Critical patent/LU81841A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06Benzothiopyrans; Hydrogenated benzothiopyrans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU81841A 1978-10-31 1979-10-30 Nouveaux composes azotes heterocycliques LU81841A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB7842679 1978-10-31
GB7842679 1978-10-31
GB7920760 1979-06-14
GB7920760 1979-06-14

Publications (1)

Publication Number Publication Date
LU81841A1 true LU81841A1 (fr) 1980-05-07

Family

ID=26269406

Family Applications (1)

Application Number Title Priority Date Filing Date
LU81841A LU81841A1 (fr) 1978-10-31 1979-10-30 Nouveaux composes azotes heterocycliques

Country Status (32)

Country Link
US (1) US4419352A (xx)
AR (1) AR230449A1 (xx)
AT (1) AT379811B (xx)
AU (1) AU528648B2 (xx)
BR (1) BR7907006A (xx)
CA (1) CA1142520A (xx)
CH (1) CH643264A5 (xx)
CS (1) CS231166B2 (xx)
CU (1) CU21123A (xx)
DD (1) DD146954A5 (xx)
DE (1) DE2943658A1 (xx)
DK (1) DK458679A (xx)
FI (1) FI67702C (xx)
FR (1) FR2440371A1 (xx)
GR (1) GR73861B (xx)
HK (1) HK66185A (xx)
HU (1) HU183087B (xx)
IE (1) IE49464B1 (xx)
IL (1) IL58579A (xx)
KE (1) KE3540A (xx)
LU (1) LU81841A1 (xx)
MA (1) MA18631A1 (xx)
MY (1) MY8500439A (xx)
NL (1) NL7907916A (xx)
NO (1) NO154522C (xx)
NZ (1) NZ191956A (xx)
PH (1) PH15442A (xx)
PL (1) PL130691B1 (xx)
PT (1) PT70392A (xx)
SE (1) SE451071B (xx)
SG (1) SG40885G (xx)
SU (1) SU1014476A3 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260306A (en) * 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
GB8402047D0 (en) * 1984-01-26 1984-02-29 Fisons Plc Nitrogen heterocycles
DE3584580D1 (de) * 1984-04-13 1991-12-12 Fisons Plc Formen und formulierungen des nedocromil-natriumsalzes.
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8607159D0 (en) * 1986-03-22 1986-04-30 Smith & Nephew Ass Pharmaceutical composition
NL8701335A (nl) * 1986-06-21 1988-01-18 Sandoz Ag Orale farmaceutische preparaten.
USRE38628E1 (en) * 1986-12-23 2004-10-19 Fisons Plc Pharmaceutical compositions
ES2058129T3 (es) * 1986-12-23 1994-11-01 Fisons Plc Composiciones farmaceuticas que comprenden una solucion acuosa de un derivado de piranoquinolina.
USH672H (en) 1986-12-31 1989-09-05 E. R. Squibb & Sons, Inc. Stable antifungal capsule formulation
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
GB8704089D0 (en) * 1987-02-21 1987-03-25 Fisons Plc Method of treatment
EP0294914A3 (en) * 1987-03-17 1990-10-10 FISONS plc Nedocromil for the treatment of dermatological disorders
US5648084A (en) * 1990-02-28 1997-07-15 Guttag; Alvin Multiple dosage medicine drop bottle
EP0546177B1 (en) * 1990-07-25 1998-01-07 Teijin Limited Benzopyran derivative, production thereof, and pharmaceutical composition containing the same
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
US7101547B1 (en) 1999-01-22 2006-09-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
EP1284972A1 (en) * 2000-05-17 2003-02-26 Cor Therapeutics, Inc. Methods for producing amino substituted chromanes and intermediates therefor
US9132116B2 (en) 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
GB0524808D0 (en) * 2005-12-05 2006-01-11 Novartis Ag Organic compounds
DE102007028095A1 (de) * 2007-06-19 2009-01-15 Bachmann, Vincent Zubereitung zur Behandlung von Hufrehe bei Equiden
FR2924344B1 (fr) * 2007-12-04 2010-04-16 Pf Medicament Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
EP2424527B8 (en) * 2009-04-29 2019-07-17 Willowcraft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1504709A (en) * 1974-12-07 1978-03-22 Fisons Ltd N-substituted quinolinone-2-carboxyl. acid der
US4143042A (en) * 1977-03-08 1979-03-06 Takeda Chemical Industries, Ltd. 1-azaxanthone-3-carboxylic acids
IL54614A (en) * 1977-05-04 1983-07-31 Fisons Ltd Dihydrodioxo-pyranoquinoline dicarboxylic acid derivatives,their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FR2440371A1 (fr) 1980-05-30
HK66185A (en) 1985-09-13
IL58579A0 (en) 1980-01-31
NZ191956A (en) 1984-05-31
FI67702B (fi) 1985-01-31
FI67702C (fi) 1985-05-10
PH15442A (en) 1983-01-18
PL130691B1 (en) 1984-08-31
MY8500439A (en) 1985-12-31
PT70392A (en) 1979-11-01
FI793369A (fi) 1980-05-01
PL219304A1 (xx) 1980-12-01
NO793469L (no) 1980-05-02
CS735979A2 (en) 1984-02-13
DE2943658C2 (xx) 1991-08-01
CA1142520A (en) 1983-03-08
GR73861B (xx) 1984-05-08
DK458679A (da) 1980-05-01
IE792074L (en) 1980-04-30
HU183087B (en) 1984-04-28
FR2440371B1 (xx) 1983-01-28
IL58579A (en) 1985-12-31
NL7907916A (nl) 1980-05-02
ATA701479A (de) 1985-07-15
SG40885G (en) 1986-05-02
AU5228779A (en) 1980-05-08
CU21123A (es) 1982-08-28
AR230449A1 (es) 1984-04-30
US4419352A (en) 1983-12-06
SU1014476A3 (ru) 1983-04-23
MA18631A1 (fr) 1980-07-01
AU528648B2 (en) 1983-05-05
BR7907006A (pt) 1980-07-15
SE7908995L (sv) 1980-05-01
DD146954A5 (de) 1981-03-11
IE49464B1 (en) 1985-10-16
DE2943658A1 (de) 1980-05-14
CS231166B2 (en) 1984-10-15
SE451071B (sv) 1987-08-31
NO154522C (no) 1986-10-08
AT379811B (de) 1986-03-10
NO154522B (no) 1986-06-30
KE3540A (en) 1985-07-12
CH643264A5 (fr) 1984-05-30

Similar Documents

Publication Publication Date Title
LU81841A1 (fr) Nouveaux composes azotes heterocycliques
SU1272984A3 (ru) Способ получени производных фталазин-4-ил-уксусной кислоты или их солей
US7553853B2 (en) Solid-state montelukast
JP2021127346A (ja) ジアザ二環式置換イミダゾピリミジンおよび呼吸障害を治療するためのその使用
JPS61191683A (ja) 新規な酸性インド−ル化合物
JPH01279866A (ja) キノリン系メバロノラクトン類
DE69732090T2 (de) Indol-2,3-dione-3-oxim derivate
JPH10502929A (ja) アミン薬物用ジオキソレニルメチルカルバメート前駆成分
JPS5965036A (ja) アラキドン酸類縁体、その製法および医薬用途
CH674368A5 (xx)
JP2961013B2 (ja) 〔(アリールアルキルピペリジン−4−イル)メチル〕−2a,3,4,5−テトラヒドロ−1(2H)−アセナフチレン−1−オン類および関連化合物
EP3596080B1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
JP3122469B2 (ja) 抗精神病剤としてのピリジンイミニル−1,2−ベイゾイソオキサゾール類及び−ベンゾイソチアゾール類
TWI746454B (zh) 化合物
PT535645E (pt) Derivados carbamato de 4-amino-3-isoxazolidonas e 3-amino-1-hidroxipirrolidin-2-onas processo para a sua preparacao e sua aplicacao como medicamentos
JPH0662575B2 (ja) ジベンズアゼピン‐6‐オン化合物
JPS5982388A (ja) 1′−〔3−(1,2−ベンズイソオキサゾ−ル−3−イル)プロピル〕スピロ−〔ベンゾフラン−2−(3h),3′−または4′−ピペリジンまたは3′−ピロリジン〕およびそれらの製造法
JPH07502007A (ja) 治療用のベンズアザピン化合物
FR2536398A1 (fr) Nouveaux composes heterocycliques
GB2035312A (en) Oxygen containing heterocylics
JPH0354645B2 (xx)
IE49800B1 (en) Benzimidazolone derivatives,process for their preparation and pharmaceutical compositions containing them
JPS6231704B2 (xx)
JPH0365338B2 (xx)
HU204264B (en) Process for producing carbamyloxylabdanes and pharmaceutical compositions containing them